Taiwan Biotech Touts Drug Derived From Chinese Medicine To Treat Cancer Patients
This article was originally published in PharmAsia News
Taiwan’s Maywufa Bio Pharmaceutical Group launched a cancer-related fatigue treatment derived from an herb used in traditional Chinese medicine and plans to investigate it for cardiovascular use with clinical trials in the United States.
You may also be interested in...
HONG KONG - Taiwan's push to do with the biotech sector what it did with IT two decades ago will be anchored on a $1.9 billion "mega fund" unveiled earlier this month
FDA should consider issuing a guidance for probiotics similar to the 2004 industry guidance for botanical drugs, panelists said at a recent Drug Information Association conference
Regulators from Japan and Taiwan met in late December to review prospects for convergence and pointed to manufacturing and new drug approvals as areas that were ripe for harmonization agreements.